| Symbol | CSBR |
|---|---|
| Name | CHAMPIONS ONCOLOGY, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | ONE UNIVERSITY PLAZA,SUITE 307, HACKENSACK, New Jersey, 07601, United States |
| Telephone | +1 201 808-8400 |
| Fax | — |
| — | |
| Website | https://www.championsoncology.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000771856 |
| Description | Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. Additional info from NASDAQ: |
Director Brainin Robert Lawrence 🟢 acquired 700.0K shares (6 derivative) of CHAMPIONS ONCOLOGY, INC. (CSBR) at $7.80 ($5.5M) Transaction Date: Jul 16, 2025 | Filing ID: 004381
Read moreDirector Brainin Robert Lawrence 🟢 acquired 66.1K shares (4 derivative) of CHAMPIONS ONCOLOGY, INC. (CSBR) at $10.10 Transaction Date: Nov 05, 2021 | Filing ID: 004342
Read more(30% Negative) CHAMPIONS ONCOLOGY, INC. (CSBR) Reports Q4 2025 Financial Results
Read moreDirector Breitfeld Philip P. 🟢 acquired 13.8K shares (1 derivative) of CHAMPIONS ONCOLOGY, INC. (CSBR) at $6.80 Transaction Date: Nov 05, 2025 | Filing ID: 050522
Read moreDirector SIDRANSKY DAVID 🟢 acquired 21.2K shares (1 derivative) of CHAMPIONS ONCOLOGY, INC. (CSBR) at $6.80 Transaction Date: Nov 05, 2025 | Filing ID: 050514
Read moreDirector Mendelson Daniel Newman 🟢 acquired 13.8K shares (1 derivative) of CHAMPIONS ONCOLOGY, INC. (CSBR) at $6.80 Transaction Date: Nov 05, 2025 | Filing ID: 050491
Read moreDirector TOBIN SCOTT R 🟢 acquired 25.5K shares (1 derivative) of CHAMPIONS ONCOLOGY, INC. (CSBR) at $6.80 Transaction Date: Nov 05, 2025 | Filing ID: 050481
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02720796 | Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or R… | Na | Sarcoma | Terminated | 2015-11-01 | 2017-11-30 | ClinicalTrials.gov |
| NCT02752932 | TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell… | Na | Head and Neck Squamous Cell Carcinoma | Completed | 2015-11-01 | 2017-10-12 | ClinicalTrials.gov |
| NCT02247037 | Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negat… | — | Triple Negative Breast Cancer | Completed | 2014-07-01 | 2019-01-22 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Drug testing on PDX per Investigator's choice (upto 4) | Drug | Approved | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT02752932 |
| PDX drug sensitivity testing | Drug | Approved | Sarcoma | TERMINATED | NCT02720796 |
| Chemotherapy | Drug | Preclinical | Triple Negative Breast Cancer | COMPLETED | NCT02247037 |